A New Generation of Vaccines in the Age of Immunotherapy

Addeo, Alfredo; Friedlaender, Alex; Giovannetti, Elisa; Russo, Alessandro; Miguel-Perez, Diego de; Arrieta, Óscar; Zorrilla, Andrés Felipe Cardona; Rolfo, Christian

doi:10.1007/s11912-021-01130-x

Cited by 14 publications

(6 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the high cost of biologics, and particularly patient-specific cellular therapeutics must also be considered. There are a broad range of potential modalities that can be locally delivered, and within these modalities a variety of agents with similar targets or mechanisms of action, with many more in pre-clinical or early phase clinical trials (24,26,27). The varied formulations and compatibilities of potentially useful therapeutics must be considered if they are to be coadministered through indwelling catheters.…”

Section: Potential Drawbacks To Intra-cavitary Therapeuticsmentioning

confidence: 99%

Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity

et al. 2022

View full text Add to dashboard Cite

Metastasis to the pleural and peritoneal cavities is a common terminal pathway for a wide variety of cancers. This article explores how these unique environments both promote aggressive tumor behavior and suppresses anti-tumor immunity, and ways in which local delivery of protein therapeutics can leverage the contained nature of these spaces to a therapeutic advantage, achieving high intra-cavital concentrations while minimizing systemic toxicity.

show abstract

Section: Potential Drawbacks To Intra-cavitary Therapeuticsmentioning

confidence: 99%

Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Also, the human papilloma virus E6/E7 antigen for Hpv associated tumors, the carcinoembryonic antigen (CEA) for colorectal and pancreatic cancers, and many more. [ 62 ] Non‐replicative Adenovirus vectors can have multiple applications in cancer therapy. That is feasible by delivering suicide genes, [ 63 ] by transferring pro‐drug‐converting enzymes to target tissues, [ 64 ] and by delivering immune‐regulatory genes to stimulate anti‐tumor response.…”

Section: Genome Engineering Technologies For Cancer Treatmentmentioning

confidence: 99%

Genome Engineering as a Therapeutic Approach in Cancer Therapy: A Comprehensive Review

Gemayel,

Chebly,

Kourie

et al. 2024

Advanced Genetics

View full text Add to dashboard Cite

Cancer is one of the foremost causes of mortality. The human genome remains stable over time. However, human activities and environmental factors have the power to influence the prevalence of certain types of mutations. This goes to the excessive progress of xenobiotics and industrial development that is expanding the territory for cancers to develop. The mechanisms involved in immune responses against cancer are widely studied. Genome editing has changed the genome‐based immunotherapy process in the human body and has opened a new era for cancer treatment. In this review, recent cancer immunotherapies and the use of genome engineering technology are largely focused on.

show abstract

“…The DNA vaccine pVAX1-MAGEA3-sPD1 is based on the MAGE-A3 antigen, enhanced with soluble PD-1 (sPD1). A series of DNA plasmids encoding MAGE-A3, and the extracellular domain of murine PD-1 (sPD1) was developed and showed immunogenicity and tumor growth inhibition in mice [ 65 ].…”

Section: Platforms Developed For Vaccine Therapymentioning

confidence: 99%

Vaccine Therapy in Non-Small Cell Lung Cancer

et al. 2022

View full text Add to dashboard Cite

Immunotherapy using immune checkpoint modulators has revolutionized the oncology field, emerging as a new standard of care for multiple indications, including non-small cell lung cancer (NSCLC). However, prognosis for patients with lung cancer is still poor. Although immunotherapy is highly effective in some cases, not all patients experience significant or durable responses, and further strategies are needed to improve outcomes. Therapeutic cancer vaccines are designed to exploit the body’s immune system to activate long-lasting memory against tumor cells that ensure tumor regression, with minimal toxicity. A unique feature of cancer vaccines lies in their complementary approach to boost antitumor immunity that could potentially act synergistically with immune checkpoint inhibitors (ICIs). However, single-line immunization against tumor epitopes with vaccine-based therapeutics has been disappointingly unsuccessful, to date, in lung cancer. The high level of success of several recent vaccines against SARS-CoV-2 has highlighted the evolving advances in science and technology in the vaccines field, raising hope that this strategy can be successfully applied to cancer treatments. In this review, we describe the biology behind the cancer vaccines, and discuss current evidence for the different types of therapeutic cancer vaccines in NSCLC, including their mechanisms of action, current clinical development, and future strategies.

show abstract

A New Generation of Vaccines in the Age of Immunotherapy

Cited by 14 publications

References 58 publications

Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity

Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity

Genome Engineering as a Therapeutic Approach in Cancer Therapy: A Comprehensive Review

Vaccine Therapy in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About